Press Releases

SAN FRANCISCO, Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammatory conditions.The data, which were presented at the 2019 Annual Meeting of the

DETROIT, Nov. 10, 2019 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute recognized its 2019 Heroes of Cancer at an evening reception held

JERSEY CITY, N.J., Nov. 10, 2019 /PRNewswire/ -- Legal-Bay LLC, The Pre Settlement Funding Company, announced today that they are preparing for an influx of hernia mesh lawsuits in the coming months.

WASHINGTON, Nov. 10, 2019 /PRNewswire/ -- The Lupus Foundation of America is developing evidence-based, online self-management education programs for people with lupus to enhan

JERSEY CITY, N.J., Nov. 10, 2019 /PRNewswire/ -- Legal-Bay LLC, The Pre Settlement Funding Company, announced today that they continue to see a large volume of IVC patients needing cash advances and expect to see payouts throughout 2020. Top IVC filter manufacturers have recently lost bellwether trials, and Legal-Bay believes this could signal a shift toward settlin

NEW YORK, Nov. 10, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting demonstrating the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for proliferative lupus neph

SINGAPORE, Nov. 9, 2019 /PRNewswire/ -- qFIBS, a novel automated algorithm developed by HistoIndex, has been shown to accurately distinguish different grades and stages of histological NASH features with a continuous measurement approach. This was highlighted in an

SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in metastatic urothelial cancer (mUC) patients with documented progression on a pl

SAN FRANCISCO, Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clinical results from the PIVOT-02 Phase 1/2 study were shared in an oral presentatio

WASHINGTON, Nov. 9, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results of an important new analysis from the landmark Phase 3 CREDENCE study, which found that INVOKANA® (canagliflozin) consistently reduced the risk of renal and cardiovascular (CV) events in patients with various levels of kidney funct